
Biosimilars Insights
Evaluation of the risks, opportunities, and strategies underlying biosimilars development and defense.
Already a Subscriber?
Evaluation of the risks, opportunities, and strategies underlying biosimilars development and defense.
Obtain a full view of market and competitive positioning with reliable and up-to-date product analysis and worldwide net sales roll ups by molecule, therapy area, and company.
Utilize a multi-client subscription service to enable drug label and label claim comparisons across geographies and therapeutic areas.
Well known for its acquisitions, Molina Healthcare expanded its existing Medicaid markets and entered a few new markets in 2020...
In DRG Blog / Jan, 2021
Signals from the southern hemisphere suggest we’re about to see a silver lining in the current pandemic: a sharp reduction in...
In DRG Blog / Jan, 2021
A review of 2019 prescription drug sales in the United States reveals Humira, Enbrel, Revlimid, Imbruvica and Keytruda to be...
In DRG Blog / Dec, 2020
CMS continues to evolve its alternative payment model strategy to include downside risk, where providers assume financial risk...
In DRG Blog / Dec, 2020
While it’s true that peripherally inserted central catheters (PICC) have been overused historically, their refined and...